{"id":213853,"date":"2010-01-22T18:06:12","date_gmt":"2010-01-22T23:06:12","guid":{"rendered":"http:\/\/blogs.wsj.com\/health\/2010\/01\/22\/what-the-new-ms-drug-does-and-what-it-doesnt-do\/"},"modified":"2010-01-22T18:06:12","modified_gmt":"2010-01-22T23:06:12","slug":"what-the-new-ms-drug-does-and-what-it-doesn%e2%80%99t-do","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/213853","title":{"rendered":"What the New MS Drug Does (and What It Doesn\u2019t Do)"},"content":{"rendered":"

\"FDA\"The FDA just approved<\/a> a new multiple sclerosis drug called Ampyra. The drug (also known as Fampridine-SR) helps some patients walk faster.<\/p>\n

Trouble walking is a serious problem for many MS patients. But only a minority of patients seem to benefit from Ampyra. In one study, 35% of people who took the drug showed improved walking speed, compared with 8% of those who took a placebo. In another study, 43% of patients showed improvement, compared with 9% who took a placebo.<\/p>\n

Still, an FDA advisory panel voted<\/a> last fall that the drug “demonstrated substantial evidence of effectiveness \u0085 as a treatment to improve walking in patients with multiple sclerosis,” and that “there are conditions under which fampridine could be considered safe.”<\/p>\n

Side effects include urinary tract infection, insomnia and dizziness, among other problems, the FDA said. Ampyra was developed by a small company called Acorda Therapeutics<\/a>. Biogen Idec, which also sells the MS drug Tysabri, will sell the drug outside of the U.S.<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

\n<\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a> <\/img><\/a>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

The FDA just approved a new multiple sclerosis drug called Ampyra. The drug (also known as Fampridine-SR) helps some patients walk faster. Trouble walking is a serious problem for many MS patients. But only a minority of patients seem to benefit from Ampyra. In one study, 35% of people who took the drug showed improved […]<\/p>\n","protected":false},"author":650,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-213853","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/213853","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/650"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=213853"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/213853\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=213853"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=213853"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=213853"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}